Brain-derived neurotrophic factor levels in newly diagnosed patients with bipolar disorder, their unaffected first-degree relatives and healthy controls.
Bipolar disorder
brain-derived neurotrophic factor
recent onset
unaffected relatives
Journal
BJPsych open
ISSN: 2056-4724
Titre abrégé: BJPsych Open
Pays: England
ID NLM: 101667931
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
entrez:
16
2
2021
pubmed:
17
2
2021
medline:
17
2
2021
Statut:
epublish
Résumé
Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives. To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls. The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status. BDNF levels were found to be 22.0% (95% CI 1.107-1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007-1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05). These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.
Sections du résumé
BACKGROUND
BACKGROUND
Brain-derived neurotrophic factor (BDNF), which facilitates neuroplasticity and synaptogenesis, may be decreased in bipolar disorder, but has not been systematically investigated in people with newly diagnosed bipolar disorder and unaffected first-degree relatives.
AIMS
OBJECTIVE
To compare BDNF levels in patients with newly diagnosed bipolar disorder, their unaffected first-degree relatives and healthy controls.
METHOD
METHODS
The study investigated plasma BDNF levels in patients (n = 371) with newly diagnosed bipolar disorder, their unaffected first-degree relatives (n = 98) and healthy controls (n = 200) using enzyme-linked immunosorbent assay. We further investigated associations between BDNF levels and illness-related variables and medication status.
RESULTS
RESULTS
BDNF levels were found to be 22.0% (95% CI 1.107-1.343) higher in patients with bipolar disorder compared with healthy controls (P < 0.001) and 15.6% higher in unaffected first-degree relatives compared with healthy controls (95% CI 1.007-1.327, P = 0.04), when adjusting for age and gender. Further, BDNF levels were positively associated with duration of illness at a trend level (P = 0.05), age (P = 0.001) and use of anti-epileptic medication (P = 0.05).
CONCLUSIONS
CONCLUSIONS
These findings suggest that BDNF levels are not decreased in the early stages of bipolar disorder and in unaffected first-degree relatives contrasting with prior findings during later stages of the illness.
Identifiants
pubmed: 33588978
doi: 10.1192/bjo.2021.9
pii: S2056472421000090
pmc: PMC8058924
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e55Références
J Psychiatr Res. 2011 Aug;45(8):995-1004
pubmed: 21550050
Acta Psychiatr Scand. 2017 Dec;136(6):607-614
pubmed: 29023633
Psychopharmacol Bull. 2001 Spring;35(2):5-49
pubmed: 12397885
Mol Psychiatry. 2014 Jul;19(7):791-800
pubmed: 23958957
Neuropharmacology. 1998 Dec;37(12):1553-61
pubmed: 9886678
Mol Psychiatry. 2009 Jan;14(1):51-9
pubmed: 17925795
Bipolar Disord. 2015 Aug;17(5):543-8
pubmed: 25846854
Psychoneuroendocrinology. 2009 Oct;34(9):1380-9
pubmed: 19473771
Chronobiol Int. 2008 Sep;25(5):819-26
pubmed: 18780207
Psychiatry Res. 2017 Oct;256:176-179
pubmed: 28645077
J Psychiatr Res. 2007 Dec;41(12):979-90
pubmed: 17239400
Psychoneuroendocrinology. 2014 Sep;47:199-211
pubmed: 25001969
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Mol Psychiatry. 2015 Sep;20(9):1108-19
pubmed: 25266124
Mol Psychiatry. 2016 Feb;21(2):216-28
pubmed: 26194180
Acta Psychiatr Scand. 2017 Jan;135(1):51-64
pubmed: 27858964
Br J Psychiatry. 2018 Sep;213(3):514-525
pubmed: 30113291
Int J Bipolar Disord. 2014 Dec;2(1):29
pubmed: 26092400
BMJ Open. 2017 Jun 23;7(6):e015462
pubmed: 28645967
Int J Neuropsychopharmacol. 2011 Sep;14(8):1091-8
pubmed: 20846461
Br J Psychiatry. 2013 Mar;202(3):212-9
pubmed: 23349295
Biol Psychiatry. 2000 Oct 15;48(8):732-9
pubmed: 11063970
BMC Med. 2015 Nov 30;13:289
pubmed: 26621529
Sci Rep. 2019 Jul 4;9(1):9655
pubmed: 31273250
Arch Gen Psychiatry. 1990 Jun;47(6):589-93
pubmed: 2190539
Psychoneuroendocrinology. 2014 Jan;39:179-183
pubmed: 24112874
World J Biol Psychiatry. 2012 Jan;13(1):39-47
pubmed: 21247257
Neurobiol Aging. 2005 Jan;26(1):115-23
pubmed: 15585351
J Affect Disord. 2012 Mar;137(1-3):151-5
pubmed: 22252095